Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motexafin lutetium

Drug Profile

Motexafin lutetium

Alternative Names: Antrin®; FP FP1; Lu-Tex; Lu-Tex/OPTRIN; Lutetium texaphyrin; Lutrin®; Optrin™; PCI 0123

Latest Information Update: 09 Jul 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacyclics
  • Class Antineoplastics; Oxidants; Texaphyrins
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Age-related macular degeneration; Atherosclerosis; Breast cancer; Cervical intraepithelial neoplasia; Coronary artery restenosis; Peripheral arterial disorders; Prostate cancer; Vascular restenosis

Most Recent Events

  • 28 Mar 2006 Motexafin lutetium is available for licensing worldwide (http://www.pharmacyclics.com)
  • 15 Nov 2004 Data presented at the American Heart Association Scientific Sessions (AHA-2004) have been added to the Ischaemic Heart Disease pharmacodynamics section
  • 12 Oct 2004 Data presented at the 16th Annual Transcatheter Cardiovascular Therapeutics conference (TCT-2004) have been added to the Ischaemic Heart Disease therapeutic trials section
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top